Treatment of Patients With Diabetic Kidney Disease

Status Not yet recruiting

Clinical Trial Summary

Due to irrespective of the limitations associated with estimated glomerular filtration rate (eGFR), it is crucial to develop new treatments that can effectively address these concerns. So, this study aimed to compare the effectiveness of SGlT2i versus ACEi in the progression of diabetic kidney disease including progression of albuminuria. Doubling of serum creatinine and need for renal replacement therapy

Clinical Trial Description

Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) worldwide and continues to be the major contributor to kidney replacement therapy (KRT). Despite the significant decline in diabetes-related complications in recent decades, the same trend cannot be observed in chronic kidney disease (CKD) patients due to DKD that requires KRT. Hence, there exists a significant requirement for novel treatment approaches that can enhance glycemic control while minimizing the risk of hypoglycemia, as well as reducing cardiovascular and renal risks within this population. Irrespective of the limitations associated with estimated glomerular filtration rate (eGFR), it is crucial to develop new treatments that can effectively address these concerns. ACE inhibitors may delay the progression of nephropathy and reduce the risks of cardiovascular events in hypertensive patients with diabetes mellitus type I and type II. SGLT2i have become the new standard of care for slowing CKD progression in patients with type 2 diabetes mellitus (T2DM, due to their specific renal and cardiovascular protective effects that are independent of the main metabolic and glucose-lowering effects. Research questions: Q1. Is there a significant effect of ACEi in treatment of patients with diabetic kidney disease. Q2: Is there is a significant effect of SGLT2i in treatment of patients with diabetic kidney disease. Q3: Which is more significantly efficient in treatment of patients with diabetic kidney disease (ACEi versus SGLT2i) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06187493
Study type	Interventional
Source	Assiut University
Contact	Ismael alaraby
Phone	+201007967808
Email	drismael83@yahoo.com
Status	Not yet recruiting
Phase	N/A
Start date	January 1, 2024
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06006689` - Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)	Phase 2
Enrolling by invitation	`NCT05530356` - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed	`NCT05086549` - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting	`NCT05008276` - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed	`NCT02276196` - Effect of LIXIsenatide on the Renal System	Phase 4
Not yet recruiting	`NCT06120569` - Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients	N/A
Completed	`NCT02545049` - Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease	Phase 3
Active, not recruiting	`NCT02237352` - Mechanisms of Diabetic Nephropathy in Ecuador
Active, not recruiting	`NCT06176599` - Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis	N/A
Recruiting	`NCT03716401` - Prognostic Imaging Biomarkers for Diabetic Kidney Disease
Terminated	`NCT03840343` - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Phase 1
Completed	`NCT01377688` - Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes	N/A
Active, not recruiting	`NCT05514548` - Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease	Phase 2
Recruiting	`NCT05507892` - Renal Mechanism of SGLT2 Inhibition	Phase 2
Not yet recruiting	`NCT06049550` - The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Not yet recruiting	`NCT05514184` - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease	N/A
Active, not recruiting	`NCT04589351` - Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe	Phase 3
Active, not recruiting	`NCT04531163` - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy	Phase 2/Phase 3
Active, not recruiting	`NCT03620773` - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes	Phase 1/Phase 2
Suspended	`NCT01878045` - Mechanisms of Diabetic Kidney Disease in American Indians

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.